Neutral
●
PRNewsWire
●
4 months ago
LONDON, June 4, 2026 /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc., (Hikma) offered the following comments on today's unanimous decision by the Supreme Court of the United States effectively ending Amarin's patent infringement litigation against the company. "Hikma has long fought for patients and their access to safe, high-qual...